Paper21079147
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Okamoto I and 19 others. J Clin Oncol, 2010. Cited by 150 papers, by iCite.
Cite this record
ConductScience Library. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. Papers, record 21079147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
- PubMed
- Publication types
- Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Carboplatin | |
| Drug Combinations | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Oxonic Acid | |
| Paclitaxel | |
| Survival Analysis | |
| Tegafur |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01874678 | A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer | Background |
Source ClinicalTrials.gov
Cited by75
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42032207 | Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy. | Jpn J Ophthalmol | 2026 | https://conductscience.org/library/papers/42032207 | PubMed |
| 39035725 | Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study. | J Natl Cancer Cent | 2023 | https://conductscience.org/library/papers/39035725 | PubMed |
| 38146645 | Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. | Thorac Cancer | 2024 | https://conductscience.org/library/papers/38146645 | PubMed |
| 37589158 | Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. | Thorac Cancer | 2023 | https://conductscience.org/library/papers/37589158 | PubMed |
| 37157831 | Patients with Lower Positive Lymph Nodes Ratio May Benefit from Preoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer. | Technol Cancer Res Treat | 2023 | https://conductscience.org/library/papers/37157831 | PubMed |
| 36961615 | Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii. | Int J Clin Oncol | 2023 | https://conductscience.org/library/papers/36961615 | PubMed |
| 36285504 | S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. | Cancer Sci | 2023 | https://conductscience.org/library/papers/36285504 | PubMed |
| 35782342 | Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. | Ther Adv Chronic Dis | 2022 | https://conductscience.org/library/papers/35782342 | PubMed |
| 35000608 | Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data. | BMC Pulm Med | 2022 | https://conductscience.org/library/papers/35000608 | PubMed |
| 34916713 | S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model. | Nagoya J Med Sci | 2021 | https://conductscience.org/library/papers/34916713 | PubMed |
| 33738585 | Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives. | Surg Today | 2022 | https://conductscience.org/library/papers/33738585 | PubMed |
| 33328765 | Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/33328765 | PubMed |
| 33159605 | Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. | Int J Clin Oncol | 2021 | https://conductscience.org/library/papers/33159605 | PubMed |
| 32996023 | Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. | Int J Clin Oncol | 2021 | https://conductscience.org/library/papers/32996023 | PubMed |
| 32961037 | Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32961037 | PubMed |
| 32567031 | Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. | Mol Cell Biochem | 2020 | https://conductscience.org/library/papers/32567031 | PubMed |
| 32426292 | Oral Chemotherapy for Treatment of Lung Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/32426292 | PubMed |
| 32351044 | A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32351044 | PubMed |
| 32060768 | A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101. | Int J Clin Oncol | 2020 | https://conductscience.org/library/papers/32060768 | PubMed |
| 31619197 | Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31619197 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21079147
GET https://conductscience.org/api/papers/v1/21079147/cited_by?page=2